

Special Issue

Recent Research on Immunotherapy in Ovarian Cancer

Message from the Guest Editor

Ovarian cancer remains one of the most lethal of gynaecological malignancies, characterised in most patients by the rapid acquisition of chemo-resistance. Substantial molecular heterogeneity at diagnosis further complicates treatment choices and efficacy.

Accordingly, more than 80% of ovarian cancer patients experience recurrent disease and more than 50% of these patients die from the disease in less than five years post-diagnosis. Therefore, there is an urgent need for new treatments. Immunotherapy has shown potential for ovarian cancer and several clinical trials testing new treatments are currently underway, including immune checkpoint inhibitors, cancer vaccines, oncolytic viruses, bispecific T-cell engagers and engineered cell therapies. Despite this expanding arsenal, there still are no approved immunotherapies for ovarian cancer. In this Special Issue of *Cancers*, experts in the field will review the current knowledge about ovarian cancer immunotherapy and the barriers that remain for clinical implementation, as well as new research aimed towards more effectively applying immunotherapy to the treatment of ovarian cancer.

Guest Editor

Dr. John Stagg

Centre de Recherche du Centre Hospitalier de l'Université de Montréal,
Université de Montréal, Montreal, QC, Canada

Deadline for manuscript submissions

closed (25 September 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/179161

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)